Metastatic Cancer Drug Market Forecast to 2028

Metastatic Cancer Drug Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Cancer Type (Breast Cancer, Lung Cancer, Liver Cancer, Hematological Cancer, Brain Cancer, Prostate Cancer, Pancreatic Cancer, and Others), Route of Administration (Intravenous, Intramuscular, Oral, and Others), Drug Class (HER2 Inhibitor, Immune Checkpoint Inhibitor, PARP Inhibitor, Kinase Inhibitor, and Others), Product (Branded and Generic & Biosimilar), and End User (Hospital, Specialty Clinic, and Others)

Report Code : TIPRE00028616 | Region : Global | Industry : Pharmaceuticals | Published Date : 12/Apr/2022

The metastatic cancer drug market size is projected to reach US$ 68,349.54 million by 2028 from US$ 51,157.97 million in 2021. It is expected to grow at a CAGR of 4.2% from 2021 to 2028. The report highlights trends prevailing in the market and factors driving the metastatic cancer drug market growth.

The growth in the metastatic cancer drug market is attributed to the increasing prevalence of metastatic cancer across the world and rising government initiatives to support research and developments in cancer treatment. However, the high cost of oncology drugs restricts the market.

Metastatic cancer is defined as an advanced cancer stage that spreads to the other body parts, and the drugs used for the treatment of advanced-stage cancer are known as metastatic cancer drugs. These drugs are used through various therapies, such as chemotherapy, immunotherapy, and targeted therapy.

Governments of various countries are introducing missions and programs for quick and effective cancer treatment. In 2016, the US Government launched the Cancer Moonshot with three ambitious goals: To accelerate scientific cancer-related discovery, foster greater collaboration, and improve data sharing. The cancer patient community and medical researchers responded with tremendous energy and ingenuity to this campaign. On February 2, 2022, the Cancer Moonshot project was relaunched by highlighting new goals of reducing the death rate of cancer by at least 50% over the next 25 years, improving the experience of people and their families living with and surviving cancer, and putting an end to cancer through these efforts. By focusing on the areas of cancer research and encouraging new investments that are most likely to benefit patients, the Cancer Moonshot has brought together a large community of investigators and clinicians dedicated to expediting research to improve the lives of patients.

In 2020, 2.7 million people in the European Union were diagnosed with the disease, and another 1.3 million people lost their lives to it. The EU has been working to tackle cancer for decades and its actions, for example tobacco control and protection from hazardous substances, have saved and prolonged lives. Europe’s Beating Cancer Plan is the EU’s response to the need for cancer treatment. It reflects a political commitment to leave no stone unturned to take action against cancer. Mobilizing the collective power of the EU to drive change for the benefit of the citizens, the Cancer Plan contains concrete, ambitious actions that will support, coordinate and complement Member States’ efforts to reduce the suffering caused by cancer. Over the coming years, it will focus on research and innovation, tap into the process of digitalization and offer new technologies, and mobilize financial instruments to support the Member States.

The European Medicines Agency introduced and authorized a drug named Trodelvy that exhibits greater benefits than its risks. In January 2021, AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu (trastuzumab deruxtecan) were granted conditional approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens. In Europe, over 531,000 breast cancer cases in women are diagnosed per year, with approximately 1 in 5 patients being HER2-positive. The impact of the disease is significant, with breast cancer responsible for more than 141,000 deaths annually in Europe.

Based on cancer type, the metastatic cancer drug market is segmented into breast cancer, lung cancer, liver cancer, hematological cancer, brain cancer, prostate cancer, pancreatic cancer, and others. The breast cancer segment accounted for the largest market share in 2021 and is anticipated to register the highest CAGR during the forecast period. Based on the route of administration, the metastatic cancer drug market is segmented into intravenous, intramuscular, oral, and others. The intravenous segment accounted for the largest market share in 2021 and is expected to register the highest CAGR during the forecast period. Based on drug class, the metastatic cancer drug market is segmented into HER2 inhibitors, immune checkpoint inhibitors, PARP inhibitors, kinase inhibitors, and others. The PARP inhibitors segment accounted for the largest market share in 2021. However, the HER2 inhibitors segment is expected to register the highest CAGR during the forecast period. Based on product, the metastatic cancer drug market is bifurcated into branded and generics and biosimilars. The branded segment accounted for a larger market share in 2021. However, the generics & biosimilars segment is estimated to register a higher CAGR during the forecast period. Based on end user, the metastatic cancer drug market is segmented into hospitals, specialty clinics, and others. The hospital segment accounted for the largest share in 2021, whereas the specialty clinic segment is estimated to register the highest CAGR during the forecast period.

With regular screening, consolations, and treatments, the market for metastatic cancer drugs in North America was constantly growing before the pandemic. The first wave of the COVID-19 crisis disrupted the consultations, follow-ups, and screenings of oncological cases. Countries such as the US and Canada reported the highest number of COVID-19 positive cases. The US-registered highest number of deaths due to the COVID-19 crisis. The chaotic situation created in the healthcare industry across the countries led to a reduced number of consultations and a smaller number of cancer cases diagnosed. For instance, international efforts suggest that the diagnoses of cancers were reduced by 40% between March 9 and May 17, 2020, compared to diagnoses averaged over the same period between 2018 and 2019. The disruption of clinical trials and drug supply to patients resulted from the pandemic crisis, thus hampering the metastatic cancer drug market.

Various organic and inorganic strategies are adopted by companies in the metastatic cancer drug market. The organic strategies mainly include product launches and product approvals. Inorganic growth strategies witnessed in the market are acquisitions, collaboration, and partnerships. These growth strategies have allowed the metastatic cancer drug market players to expand their business, enhance their geographic presence, and contribute to the overall market growth. Additionally, various growth strategies, such as acquisitions and partnerships, helped them strengthen their customer base and extend their product portfolios. A few of the significant developments by key players in the metastatic cancer drug market are listed below.

In January 2022, AbbVie announced that the US FDA granted Breakthrough Therapy Designation (BTD) to investigate the telisotuzumab vedotin (Teliso-V) for the treatment of patients with advanced/metastatic epidermal growth factor receptor (EGFR) wild type, nonsquamous non-small cell lung cancer (NSCLC) with high levels of c-Met overexpression whose disease has progressed on or after platinum-based therapy.

A few of the major primary and secondary sources referred to while preparing the report on the metastatic cancer drug market are the National Center for Health Statistics (a department of the US Department of Health & Human Services), Centers for Disease Control and Prevention (CDC), World Health Organization (WHO), and Organization for Economic Co-operation and Development (OECD).

Government Initiatives to Support Developments in Cancer Treatment to Drive Global Metastatic Cancer Drug Market

According to our new research study on "Metastatic Cancer Drug Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Cancer Type, Route of Administration, Drug Class, Product, and End User," the metastatic cancer drug market size is expected to grow from US$ 51,157.97 million in 2021 to US$ 68,349.54 million by 2028. It is estimated to grow at a CAGR of 4.2% from 2021 to 2028. Factors driving the market's growth are the high prevalence of metastatic cancer and government initiatives to support developments in cancer treatment.

Government organizations of various countries are introducing missions and programs for quick and effective cancer treatment. In 2016, the Government of the US launched the Cancer Moonshot with three ambitious goals: To accelerate scientific cancer-related discovery, foster greater collaboration, and improve data sharing. The cancer patient community and medical researchers responded with tremendous energy and ingenuity to this campaign. On February 2, 2022, the Cancer Moonshot project was relaunched by highlighting new goals of reducing the death rate of cancer by at least 50% over the next 25 years, improving the experience of people and their families living with and surviving cancer, and putting an end to cancer through these efforts. By focusing on the areas of cancer research and encouraging new investments that are most likely to benefit patients, the Cancer Moonshot has brought together a large community of investigators and clinicians dedicated to expediting research to improve patient lives.

In 2020, 2.7 million people in the European Union were diagnosed with the disease, and another 1.3 million people lost their lives to it. The EU has been working to tackle cancer for decades, and its actions, for example, tobacco control and protection from hazardous substances, have saved and prolonged lives. Europe’s Beating Cancer Plan is the EU’s response to the need for cancer treatment. It reflects a political commitment to leave no stone unturned to take action against cancer. Mobilizing the collective power of the EU to drive change for the benefit of the citizens, the Cancer Plan contains concrete, ambitious actions that will support, coordinate and complement Member States’ efforts to reduce the suffering caused by cancer. Over the coming years, it will focus on research and innovation, tap into the process of digitalization and offer new technologies, and mobilize financial instruments to support the Member States.

F. Hoffmann-La Roche Ltd; AbbVie Inc.; Amgen Inc.; Novartis AG; ASTRAZENECA PLC.; Eli Lily and Company; Merck KGaA; Pfizer Inc.; Johnson & Johnson Services, Inc.; and Bristol-Myers Squibb Company are the leading companies operating in the metastatic cancer drug market.

Metastatic Cancer Drugs Market by Region, 2021 (%)

Source: The Insight Partners Analysis

The metastatic cancer drug market is analyzed on the basis of cancer type, route of administration, drug class, product, end user, and geography.

The metastatic cancer drug market is analyzed on the basis of cancer type, route of administration, drug class, product, end user, and geography. Based on cancer type, the market is segmented into breast cancer, lung cancer, liver cancer, hematological cancer, brain cancer, prostate cancer, pancreatic cancer, and others. Based on route of administration, the market is segmented into intravenous, intramuscular, oral, and others. Based on drug class, the metastatic cancer drug market is segmented into HER2 inhibitors, immune checkpoint inhibitors, PARP inhibitors, kinase inhibitors, and others. Based on product, the market is bifurcated into branded products and generics and biosimilars. Based on end user, the market is segmented into hospitals, specialty clinics, and others.

By geography, the metastatic cancer drug market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

TABLE OF CONTENTS

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 Global Metastatic Cancer Drugs Market – By Cancer Type

1.3.2 Global Metastatic Cancer Drugs Market – By Route of Administration

1.3.3 Global Metastatic Cancer Drugs Market – By Drug Class

1.3.4 Global Metastatic Cancer Drugs Market – By Product

1.3.5 Global Metastatic Cancer Drugs Market – By End User

1.3.6 Global Metastatic Cancer Drugs Market – By Geography

2. Metastatic Cancer Drugs Market – Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Global Metastatic Cancer Drugs Market – Market Landscape

4.1 Overview

4.2 PEST Analysis

4.2.1 North America– PEST Analysis

4.2.2 Europe– PEST Analysis

4.2.3 Asia Pacific– PEST Analysis

4.2.4 South & Central America– PEST Analysis

4.2.5 Middle East & Africa– PEST Analysis

4.3 Expert Opinion

5. Metastatic Cancer Drugs Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 High Prevalence of Metastatic Cancer

5.1.2 Government Initiatives to Support Developments in Cancer Treatment

5.2 Market Restraints

5.2.1 High Cost of Oncology Drugs

5.3 Market Opportunities

5.3.1 Investments in Artificial Intelligence for Oncology Drug Development

5.4 Future Trends

5.4.1 Increase in Launch of Metastatic Cancer Drugs

5.5 Impact analysis

6. Metastatic Cancer Drugs Market – Global Analysis

6.1 Global Metastatic Cancer Drugs Market Revenue Forecast and Analysis

6.1.1 Global Metastatic Cancer Drugs Market, By Geography - Forecast and Analysis

6.1.2 Global Metastatic Cancer Drugs Market – Market Potential Analysis, By Region

6.2 Company Analysis

6.2.1 Market Positioning of Key Players

6.2.2 Comparative Company Analysis

6.2.3 Growth Strategy Analysis

6.2.4 Performance of Key Players

6.2.4.1 Celgene Corporation

6.2.4.2 Novartis AG

7. Metastatic Cancer Drug Market Analysis – By Cancer Type

7.1 Overview

7.2 Metastatic Cancer Drug Market Revenue Share, by Cancer Type (2021 and 2028)

7.3 Breast Cancer

7.3.1 Overview

7.3.2 Breast Cancer: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

7.4 Lung Cancer

7.4.1 Overview

7.4.2 Lung Cancer: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

7.5 Liver Cancer

7.5.1 Overview

7.5.2 Liver Cancer: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

7.6 Hematological Cancer

7.6.1 Overview

7.6.2 Hematological Cancer: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

7.7 Brain Cancer

7.7.1 Overview

7.7.2 Brain Cancer: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

7.8 Prostate Cancer

7.8.1 Overview

7.8.2 Prostate Cancer: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

7.9 Pancreatic Cancer

7.9.1 Overview

7.9.2 Pancreatic Cancer: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

7.10 Others

7.10.1 Overview

7.10.2 Others: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

8. Metastatic Cancer Drug Market – By Route of Administration

8.1 Overview

8.2 Metastatic Cancer Drug Market, by Route of Administration, 2021 and 2028 (%)

8.3 Intravenous

8.3.1 Overview

8.3.2 Intravenous: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

8.4 Intramuscular

8.4.1 Overview

8.4.2 Intramuscular: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

8.5 Oral

8.5.1 Overview

8.5.2 Oral: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

8.6 Others

8.6.1 Overview

8.6.2 Others: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

9. Metastatic Cancer Drug Market – By Drug Class

9.1 Overview

9.2 Metastatic Cancer Drug Market, by Drug Class, 2021 and 2028 (%)

9.3 HER2 Inhibitors

9.3.1 Overview

9.3.2 HER2 Inhibitors: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

9.4 Immune Checkpoints Inhibitors

9.4.1 Overview

9.4.2 Immune Checkpoints Inhibitors: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

9.5 PARP Inhibitors

9.5.1 Overview

9.5.2 PARP Inhibitors: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

9.6 Kinase Inhibitors

9.6.1 Overview

9.6.2 Kinase Inhibitors: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

9.7 Others

9.7.1 Overview

9.7.2 Others: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

10. Metastatic Cancer Drug Market – By Product

10.1 Overview

10.2 Metastatic Cancer Drug Market, by Product, 2021 and 2028 (%)

10.3 Branded

10.3.1 Overview

10.3.2 Branded: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

10.4 Generics and Biosimilars

10.4.1 Overview

10.4.2 Generics and Biosimilars: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

11. Metastatic Cancer Drug Market – By End User

11.1 Overview

11.2 Metastatic Cancer Drug Market, by End User, 2021 and 2028 (%)

11.3 Hospital

11.3.1 Overview

11.3.2 Hospitals: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

11.4 Specialty Clinic

11.4.1 Overview

11.4.2 Specialty Clinics: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

11.5 Others

11.5.1 Overview

11.5.2 Others: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

12. Metastatic Cancer Drugs Market – Regional Analysis

12.1 North America: Metastatic Cancer Drugs Market

12.1.1 Overview

12.1.2 North America: Metastatic Cancer Drug Market - Revenue and Forecast to 2028 (USD Million)

12.1.3 North America: Metastatic Cancer Drug Market, by Cancer Type – Revenue and Forecast to 2028 (USD Million)

12.1.4 North America: Metastatic Cancer Drug Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

12.1.5 North America: Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)

12.1.6 North America: Metastatic Cancer Drug Market, by Product – Revenue and Forecast to 2028 (USD Million)

12.1.7 North America: Metastatic Cancer Drug Market, by End User – Revenue and Forecast to 2028 (USD Million)

12.1.8 North America: Metastatic Cancer Drug Market, by Country, 2021 & 2028 (%)

12.1.8.1 US: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.1.8.1.1 US: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.1.8.1.2 US: Metastatic Cancer Drug Market, by Cancer Type – Revenue and Forecast to 2028 (USD Million)

12.1.8.1.3 US: Metastatic Cancer Drug Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

12.1.8.1.4 US: Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)

12.1.8.1.5 US: Metastatic Cancer Drug Market, by Product – Revenue and Forecast to 2028 (USD Million)

12.1.8.1.6 US: Metastatic Cancer Drug Market, by End User – Revenue and Forecast to 2028 (USD Million)

12.1.8.2 Canada: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.1.8.2.1 Canada: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.1.8.2.2 Canada: Metastatic Cancer Drug Market, by Cancer Type – Revenue and Forecast to 2028 (USD Million)

12.1.8.2.3 Canada: Metastatic Cancer Drug Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

12.1.8.2.4 Canada: Metastatic Cancer Drug Market, by Drug Class– Revenue and Forecast to 2028 (USD Million)

12.1.8.2.5 Canada: Metastatic Cancer Drug Market, by Product – Revenue and Forecast to 2028 (USD Million)

12.1.8.2.6 Canada: Metastatic Cancer Drug Market, by End User – Revenue and Forecast to 2028 (USD Million)

12.1.8.3 Mexico: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.1.8.3.1 Mexico: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.1.8.3.2 Mexico: Metastatic Cancer Drug Market, by Cancer Type – Revenue and Forecast to 2028 (USD Million)

12.1.8.3.3 Mexico: Metastatic Cancer Drug Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

12.1.8.3.4 Mexico: Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)

12.1.8.3.5 Mexico: Metastatic Cancer Drug Market, by Product– Revenue and Forecast to 2028 (USD Million)

12.1.8.3.6 Mexico: Metastatic Cancer Drug Market, by End User – Revenue and Forecast to 2028 (USD Million)

12.2 Europe: Metastatic Cancer Drugs Market

12.2.1 Overview

12.2.2 Europe: Metastatic Cancer Drug Market - Revenue and Forecasts to 2028 (US$ Mn)

12.2.3 Europe: Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, By Cancer Type (US$ Mn)

12.2.4 Europe: Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, By Route of Administration (US$ Mn)

12.2.5 Europe: Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, by Drug Class (US$ Mn)

12.2.6 Europe: Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, by Product (US$ Mn)

12.2.7 Europe: Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, by End User (US$ Mn)

12.2.8 Europe: Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, By Country (%)

12.2.8.1 UK: Metastatic Cancer Drug Market - Revenue and Forecasts to 2028 (US$ Mn)

12.2.8.1.1 UK: Metastatic Cancer Drug Market - Revenue and Forecasts to 2028 (US$ Mn)

12.2.8.1.2 UK: Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, By Cancer Type (US$ Mn)

12.2.8.1.3 UK: Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, By Route of Administration (US$ Mn)

12.2.8.1.4 UK: Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, by Drug Class (US$ Mn)

12.2.8.1.5 UK: Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, by Product (US$ Mn)

12.2.8.1.6 UK: Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, by End User (US$ Mn)

12.2.8.2 Germany Metastatic Cancer Drug Market - Revenue and Forecasts to 2028 (US$ Mn)

12.2.8.2.1 Germany Metastatic Cancer Drug Market - Revenue and Forecasts to 2028 (US$ Mn)

12.2.8.2.2 Germany Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, By Cancer Type (US$ Mn)

12.2.8.2.3 Germany Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, By Route of Administration (US$ Mn)

12.2.8.2.4 Germany Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, by Drug Class (US$ Mn)

12.2.8.2.5 Germany Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, by Product (US$ Mn)

12.2.8.2.6 Germany Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, by End User (US$ Mn)

12.2.8.3 France Metastatic Cancer Drug Market - Revenue and Forecasts to 2028 (US$ Mn)

12.2.8.3.1 France Metastatic Cancer Drug Market - Revenue and Forecasts to 2028 (US$ Mn)

12.2.8.3.2 France Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, By Cancer Type (US$ Mn)

12.2.8.3.3 France Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, By Route of Administration (US$ Mn)

12.2.8.3.4 France Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, by Drug Class (US$ Mn)

12.2.8.3.5 France Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, by Product (US$ Mn)

12.2.8.3.6 France Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, by End User (US$ Mn)

12.2.8.4 Italy Metastatic Cancer Drug Market - Revenue and Forecasts to 2028 (US$ Mn)

12.2.8.4.1 Italy Metastatic Cancer Drug Market - Revenue and Forecasts to 2028 (US$ Mn)

12.2.8.4.2 Italy Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, By Cancer Type (US$ Mn)

12.2.8.4.3 Italy Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, By Route of Administration (US$ Mn)

12.2.8.4.4 Italy Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, by Drug Class (US$ Mn)

12.2.8.4.5 Italy Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, by Product (US$ Mn)

12.2.8.4.6 Italy Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, by End User (US$ Mn)

12.2.8.5 Spain Metastatic Cancer Drug Market - Revenue and Forecasts to 2028 (US$ Mn)

12.2.8.5.1 Spain Metastatic Cancer Drug Market - Revenue and Forecasts to 2028 (US$ Mn)

12.2.8.5.2 Spain Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, By Cancer Type (US$ Mn)

12.2.8.5.3 Spain Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, By Route of Administration (US$ Mn)

12.2.8.5.4 Spain Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, by Drug Class (US$ Mn)

12.2.8.5.5 Spain Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, by Product (US$ Mn)

12.2.8.5.6 Spain Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, by End User (US$ Mn)

12.2.8.6 Rest of Europe: Metastatic Cancer Drug Market - Revenue and Forecasts to 2028 (US$ Mn)

12.2.8.6.1 Rest of Europe: Metastatic Cancer Drug Market - Revenue and Forecasts to 2028 (US$ Mn)

12.2.8.6.2 Rest of Europe: Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, By Cancer Type (US$ Mn)

12.2.8.6.3 Rest of Europe: Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, By Route of Administration (US$ Mn)

12.2.8.6.4 Rest of Europe: Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, by Drug Class Type (US$ Mn)

12.2.8.6.5 Rest of Europe: Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, by Product (US$ Mn)

12.2.8.6.6 Rest of Europe: Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, by End User (US$ Mn)

12.3 Asia Pacific: Metastatic Cancer Drugs Market

12.3.1 Overview

12.3.2 Asia Pacific: Metastatic Cancer Drug Market - Revenue and Forecast to 2028 (USD Million)

12.3.3 Asia Pacific: Metastatic Cancer Drug Market, By Cancer Type, 2019–2028 (USD Million)

12.3.4 Asia Pacific: Metastatic Cancer Drug Market, By Route of Administration, 2019–2028 (USD Million)

12.3.5 Asia Pacific: Metastatic Cancer Drug Market, by Drug Class, 2019–2028 (USD Million)

12.3.6 Asia Pacific: Metastatic Cancer Drug Market, by Product, 2019–2028 (USD Million)

12.3.7 Asia Pacific: Metastatic Cancer Drug Market, by End User, 2019–2028 (USD Million)

12.3.8 Asia Pacific: Metastatic Cancer Drug Market, by Country, 2021 & 2028 (%)

12.3.8.1 China: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.3.8.1.1 China: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.3.8.1.2 China: Metastatic Cancer Drug Market, By Cancer Type, 2019–2028 (USD Million)

12.3.8.1.3 China: Metastatic Cancer Drug Market, By Route of Administration, 2019–2028 (USD Million)

12.3.8.1.4 China: Metastatic Cancer Drug Market, by Drug Class, 2019–2028 (USD Million)

12.3.8.1.5 China: Metastatic Cancer Drug Market, by Product, 2019–2028 (USD Million)

12.3.8.1.6 China: Metastatic Cancer Drug Market, by End User, 2019–2028 (USD Million)

12.3.8.2 Japan: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.3.8.2.1 Japan: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.3.8.2.2 Japan: Metastatic Cancer Drug Market, By Cancer Type– Revenue and Forecast to 2028 (USD Million)

12.3.8.2.3 Japan: Metastatic Cancer Drug Market, By Route of Administration, 2019–2028 (USD Million)

12.3.8.2.4 Japan: Metastatic Cancer Drug Market, by Drug Class, 2019–2028 (USD Million)

12.3.8.2.5 Japan: Metastatic Cancer Drug Market, by Product, 2019–2028 (USD Million)

12.3.8.2.6 Japan: Metastatic Cancer Drug Market, by End User, 2019–2028 (USD Million)

12.3.8.3 India: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.3.8.3.1 India: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.3.8.3.2 India: Metastatic Cancer Drug Market, By Cancer Type, 2019–2028 (USD Million)

12.3.8.3.3 India: Metastatic Cancer Drug Market, By Route of Administration, 2019–2028 (USD Million)

12.3.8.3.4 India: Metastatic Cancer Drug Market, by Drug Class, 2019–2028 (USD Million)

12.3.8.3.5 India: Metastatic Cancer Drug Market, by Product, 2019–2028 (USD Million)

12.3.8.3.6 India: Metastatic Cancer Drug Market, by End User, 2019–2028 (USD Million)

12.3.8.4 Australia: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.3.8.4.1 Australia: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.3.8.4.2 Australia: Metastatic Cancer Drug Market, By Cancer Type, 2019–2028 (USD Million)

12.3.8.4.3 Australia: Metastatic Cancer Drug Market, By Route of Administrations, 2019–2028 (USD Million)

12.3.8.4.4 Australia: Metastatic Cancer Drug Market, by Drug Class, 2019–2028 (USD Million)

12.3.8.4.5 Australia: Metastatic Cancer Drug Market, by Product, 2019–2028 (USD Million)

12.3.8.4.6 Australia: Metastatic Cancer Drug Market, by End User, 2019–2028 (USD Million)

12.3.8.5 South Korea: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.3.8.5.1 South Korea: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.3.8.5.2 South Korea: Metastatic Cancer Drug Market, By Cancer Type, 2019–2028 (USD Million)

12.3.8.5.3 South Korea: Metastatic Cancer Drug Market, By Route of Administration, 2019–2028 (USD Million)

12.3.8.5.4 South Korea: Metastatic Cancer Drug Market, by Drug Class, 2019–2028 (USD Million)

12.3.8.5.5 South Korea: Metastatic Cancer Drug Market, by Product, 2019–2028 (USD Million)

12.3.8.5.6 South Korea: Metastatic Cancer Drug Market, by End User, 2019–2028 (USD Million)

12.3.8.6 Rest of Asia Pacific: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.3.8.6.1 Rest of Asia Pacific: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.3.8.6.2 Rest of Asia Pacific: Metastatic Cancer Drug Market, By Cancer Type, 2019–2028 (USD Million)

12.3.8.6.3 Rest of Asia Pacific: Metastatic Cancer Drug Market, By Route of Administration, 2019–2028 (USD Million)

12.3.8.6.4 Rest of Asia Pacific: Metastatic Cancer Drug Market, by Drug Class, 2019–2028 (USD Million)

12.3.8.6.5 Rest of Asia Pacific: Metastatic Cancer Drug Market, by Product, 2019–2028 (USD Million)

12.3.8.6.6 Rest of Asia Pacific: Metastatic Cancer Drug Market, by End User, 2019–2028 (USD Million)

12.4 Middle East and Africa: Metastatic Cancer Drugs Market

12.4.1 Overview

12.4.2 Middle East and Africa: Metastatic Cancer Drugs Market – Revenue and Forecast to 2028 (US$ ‘Million)

12.4.3 Middle East & Africa Metastatic Cancer Drug Market, by Cancer Type– Revenue and Forecast to 2028 (USD Million)

12.4.4 Middle East & Africa Metastatic Cancer Drug Market, by Route of Administration– Revenue and Forecast to 2028 (USD Million)

12.4.5 Middle East & Africa Metastatic Cancer Drug Market, by Drug Class– Revenue and Forecast to 2028 (USD Million)

12.4.6 Middle East & Africa Metastatic Cancer Drug Market, by Product– Revenue and Forecast to 2028 (USD Million)

12.4.7 Middle East & Africa: Metastatic Cancer Drug Market, by End User, 2019–2028 (USD Million)

12.4.8 Middle East & Africa: Metastatic Cancer Drug Market, by Country, 2021 & 2028 (%)

12.4.8.1 Saudi Arabia: Metastatic Cancer Drug Market - Revenue and Forecast to 2028 (USD Million)

12.4.8.1.1 Saudi Arabia: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.4.8.1.2 Saudi Arabia Metastatic Cancer Drug Market, by Cancer Type– Revenue and Forecast to 2028 (USD Million)

12.4.8.1.3 Saudi Arabia Metastatic Cancer Drug Market, by Route of Administration– Revenue and Forecast to 2028 (USD Million)

12.4.8.1.4 Saudi Arabia Metastatic Cancer Drug Market, by Drug Class– Revenue and Forecast to 2028 (USD Million)

12.4.8.1.5 Saudi Arabia Metastatic Cancer Drug Market, by Product– Revenue and Forecast to 2028 (USD Million)

12.4.8.1.6 Saudi Arabia: Metastatic Cancer Drug Market, by End User, 2019–2028 (USD Million)

12.4.8.2 UAE: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.4.8.2.1 UAE: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.4.8.2.2 UAE Metastatic Cancer Drug Market, by Cancer Type– Revenue and Forecast to 2028 (USD Million)

12.4.8.2.3 UAE Metastatic Cancer Drug Market, by Route of Administration– Revenue and Forecast to 2028 (USD Million)

12.4.8.2.4 UAE Metastatic Cancer Drug Market, by Drug Class– Revenue and Forecast to 2028 (USD Million)

12.4.8.2.5 UAE Metastatic Cancer Drug Market, by Product– Revenue and Forecast to 2028 (USD Million)

12.4.8.2.6 UAE: Metastatic Cancer Drug Market, by End User, 2019–2028 (USD Million)

12.4.8.3 South Africa: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.4.8.3.1 South Africa: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.4.8.3.2 South Africa Metastatic Cancer Drug Market, by Cancer Type– Revenue and Forecast to 2028 (USD Million)

12.4.8.3.3 South Africa Metastatic Cancer Drug Market, by Route of Administration– Revenue and Forecast to 2028 (USD Million)

12.4.8.3.4 South Africa Metastatic Cancer Drug Market, by Drug Class– Revenue and Forecast to 2028 (USD Million)

12.4.8.3.5 South Africa Metastatic Cancer Drug Market, by Product– Revenue and Forecast to 2028 (USD Million)

12.4.8.3.6 South Africa: Metastatic Cancer Drug Market, by End User, 2019–2028 (USD Million)

12.4.8.4 Rest of Middle East and Africa: Metastatic Cancer Drug Market - Revenue and Forecast to 2028 (USD Million)

12.4.8.4.1 Rest of Middle East and Africa: Metastatic Cancer Drug Market - Revenue and Forecast to 2028 (USD Million)

12.4.8.4.2 Rest of Middle East & Africa Metastatic Cancer Drug Market, by Cancer Type– Revenue and Forecast to 2028 (USD Million)

12.4.8.4.3 Rest of Middle East & Africa Metastatic Cancer Drug Market, by Route of Administration– Revenue and Forecast to 2028 (USD Million)

12.4.8.4.4 Rest of Middle East & Africa Metastatic Cancer Drug Market, by Drug Class– Revenue and Forecast to 2028 (USD Million)

12.4.8.4.5 Rest of Middle East & Africa Metastatic Cancer Drug Market, by Product– Revenue and Forecast to 2028 (USD Million)

12.4.8.4.6 Rest of Middle East & Africa: Metastatic Cancer Drug Market, by End User, 2019–2028 (USD Million)

12.5 South and Central America: Metastatic Cancer Drugs Market

12.5.1 Overview

12.5.2 South and Central America: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.5.3 South and Central America: Metastatic Cancer Drug Market, by Cancer Type, 2019–2028 (USD Million)

12.5.4 South and Central America: Metastatic Cancer Drug Market, by Route of Administration, 2019–2028 (USD Million)

12.5.5 South and Central America: Metastatic Cancer Drug Market, by Drug Class, 2019–2028 (USD Million)

12.5.6 South and Central America: Metastatic Cancer Drug Market, by Product, 2019–2028 (USD Million)

12.5.7 South and Central America: Metastatic Cancer Drug Market, by End User, 2019–2028 (USD Million)

12.5.8 South and Central America: Metastatic Cancer Drug Market, by Country, 2021 & 2028 (%)

12.5.8.1 Brazil: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.5.8.1.1 Brazil: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.5.8.1.2 Brazil: Metastatic Cancer Drug Market, by Cancer Type, 2019–2028 (USD Million)

12.5.8.1.3 Brazil: Metastatic Cancer Drug Market, by Route of Administration, 2019–2028 (USD Million)

12.5.8.1.4 Brazil: Metastatic Cancer Drug Market, by Drug Class, 2019–2028 (USD Million)

12.5.8.1.5 Brazil: Metastatic Cancer Drug Market, by Product, 2019–2028 (USD Million)

12.5.8.1.6 Brazil: Metastatic Cancer Drug Market, by End User, 2019–2028 (USD Million)

12.5.8.2 Argentina: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.5.8.2.1 Argentina: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.5.8.2.2 Argentina: Metastatic Cancer Drug Market, by Cancer Type, 2019–2028 (USD Million)

12.5.8.2.3 Argentina: Metastatic Cancer Drug Market, by Route of Administration, 2019–2028 (USD Million)

12.5.8.2.4 Argentina: Metastatic Cancer Drug Market, by Drug Class, 2019–2028 (USD Million)

12.5.8.2.5 Argentina: Metastatic Cancer Drug Market, by Product, 2019–2028 (USD Million)

12.5.8.2.6 Argentina: Metastatic Cancer Drug Market, by End User, 2019–2028 (USD Million)

12.5.8.3 Rest of South and Central America: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.5.8.3.1 Rest of South and Central America: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

12.5.8.3.2 Rest of South and Central America: Metastatic Cancer Drug Market, by Cancer Type, 2019–2028 (USD Million)

12.5.8.3.3 Rest of South and Central America: Metastatic Cancer Drug Market, by Route of Administration, 2019–2028 (USD Million)

12.5.8.3.4 Rest of South and Central America: Metastatic Cancer Drug Market, by Drug Class, 2019–2028 (USD Million)

12.5.8.3.5 Rest of South and Central America: Metastatic Cancer Drug Market, by Product, 2019–2028 (USD Million)

12.5.8.3.6 Rest of South and Central America: Metastatic Cancer Drug Market, by End User, 2019–2028 (USD Million)

13. Impact of COVID-19 Pandemic on Global Metastatic Cancer Drugs Market

13.1 North America: Impact Assessment of COVID-19 Pandemic

13.2 Europe: Impact Assessment of COVID-19 Pandemic

13.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic

13.4 Middle East & Africa: Impact Assessment of COVID-19 Pandemic

13.5 South and Central America: Impact Assessment of COVID-19 Pandemic

14. Metastatic Cancer Drug Market –Industry Landscape

14.1 Overview

14.2 Growth Strategies in the Metastatic Cancer Drug Market, 2021-2028

14.3 Inorganic Developments

14.3.1 Overview

14.4 Organic Growth Strategies

14.4.1 Overview

15. Company Profiles

15.1 AbbVie Inc.

15.1.1 Key Facts

15.1.2 Business Description

15.1.3 Products and Services

15.1.4 Financial Overview

15.1.5 SWOT Analysis

15.1.6 Key Developments

15.2 Amgen Inc.

15.2.1 Key Facts

15.2.2 Business Description

15.2.3 Products and Services

15.2.4 Financial Overview

15.2.5 SWOT Analysis

15.2.6 Key Developments

15.3 Bristol-Myers Squibb Company

15.3.1 Key Facts

15.3.2 Business Description

15.3.3 Products and Services

15.3.4 Financial Overview

15.3.5 SWOT Analysis

15.3.6 Key Developments

15.4 F. HOFFMANN-LA ROCHE LTD.

15.4.1 Key Facts

15.4.2 Business Description

15.4.3 Products and Services

15.4.4 Financial Overview

15.4.5 SWOT Analysis

15.4.6 Key Developments

15.5 Novartis AG

15.5.1 Key Facts

15.5.2 Business Description

15.5.3 Products and Services

15.5.4 Financial Overview

15.5.5 SWOT Analysis

15.5.6 Key Developments

15.6 Astrazeneca

15.6.1 Key Facts

15.6.2 Business Description

15.6.3 Products and Services

15.6.4 Financial Overview

15.6.5 SWOT Analysis

15.6.6 Key Developments

15.7 Eli Lilly and Company.

15.7.1 Key Facts

15.7.2 Business Description

15.7.3 Products and Services

15.7.4 Financial Overview

15.7.5 SWOT Analysis

15.7.6 Key Developments

15.8 MERCK KGaA

15.8.1 Key Facts

15.8.2 Business Description

15.8.3 Products and Services

15.8.4 Financial Overview

15.8.5 SWOT Analysis

15.8.6 Key Developments

15.9 Pfizer Inc. (Arena Pharmaceutical GmbH)

15.9.1 Key Facts

15.9.2 Business Description

15.9.3 Products and Services

15.9.4 Financial Overview

15.9.5 SWOT Analysis

15.9.6 Key Developments

15.10 Johnson and Johnson Services, Inc.

15.10.1 Key Facts

15.10.2 Business Description

15.10.3 Products and Services

15.10.4 Financial Overview

15.10.5 SWOT Analysis

15.10.6 Key Developments

16. Appendix

16.1 About The Insight Partners

16.2 Glossary of Terms

LIST OF TABLES.

Table 1. North America: Metastatic Cancer Drug Market, by Cancer Type – Revenue and Forecast to 2028 (USD Million)

Table 2. North America: Metastatic Cancer Drug Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

Table 3. North America: Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)

Table 4. North America: Metastatic Cancer Drug Market, by Product – Revenue and Forecast to 2028 (USD Million)

Table 5. North America: Metastatic Cancer Drug Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 6. US: Metastatic Cancer Drug Market, by Cancer Type – Revenue and Forecast to 2028 (USD Million)

Table 7. US: Metastatic Cancer Drug Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

Table 8. US: Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)

Table 9. US: Metastatic Cancer Drug Market, by Product – Revenue and Forecast to 2028 (USD Million)

Table 10. US: Metastatic Cancer Drug Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 11. Canada: Metastatic Cancer Drug Market, by Cancer Type - Revenue and Forecast to 2028 (USD Million)

Table 12. Canada: Metastatic Cancer Drug Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)

Table 13. Canada: Metastatic Cancer Drug Market, by Drug Class - Revenue and Forecast to 2028 (USD Million)

Table 14. Canada: Metastatic Cancer Drug Market, by Product - Revenue and Forecast to 2028 (USD Million)

Table 15. Canada: Metastatic Cancer Drug Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 16. Mexico: Metastatic Cancer Drug Market, by Cancer Type – Revenue and Forecast to 2028 (USD Million)

Table 17. Mexico: Metastatic Cancer Drug Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

Table 18. Mexico: Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)

Table 19. Mexico: Metastatic Cancer Drug Market, by Product – Revenue and Forecast to 2028 (USD Million)

Table 20. Mexico: Metastatic Cancer Drug Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 21. Europe: Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, By Cancer Type (US$ Mn).

Table 22. Europe: Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, By Route of Administration (US$ Mn).

Table 23. Europe: Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, by Drug Class (US$ Mn)

Table 24. Europe: Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, by Product (US$ Mn)

Table 25. Europe: Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, by End User (US$ Mn)

Table 26. UK: Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, By Cancer Type US$ Mn)

Table 27. UK: Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, By Route of Administration US$ Mn)

Table 28. UK: Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, by Drug Class (US$ Mn)

Table 29. UK: Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, by Product (US$ Mn)

Table 30. UK: Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, by End User US$ Mn)

Table 31. Germany Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, By Cancer Type (US$ Mn)

Table 32. Germany Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, By Route of Administration (US$ Mn)

Table 33. Germany Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, by Drug Class US$ Mn)

Table 34. Germany Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, by Product (US$ Mn)

Table 35. Germany Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, by End User US$ Mn)

Table 36. France Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, By Cancer Type (US$ Mn)

Table 37. France Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, By Route of Administration (US$ Mn)

Table 38. France Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, by Drug Class (US$ Mn)

Table 39. France Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, by Product (US$ Mn)

Table 40. France Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, by End User (US$ Mn)

Table 41. Italy Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, By Cancer Type (US$ Mn)

Table 42. Italy Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, By Route of Administration (US$ Mn)

Table 43. Italy Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, by Drug Class (US$ Mn)

Table 44. Italy Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, by Product (US$ Mn)

Table 45. Italy Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, by End User (US$ Mn)

Table 46. Spain Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, By Cancer Type (US$ Mn)

Table 47. Spain Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, By Route of Administration (US$ Mn)

Table 48. Spain Metastatic Cancer Drug Market Revenue and Forecast to 2028, by Drug Class (USD Million)

Table 49. Spain Metastatic Cancer Drug Market Revenue and Forecast to 2028, by Product (USD Million)

Table 50. Spain Metastatic Cancer Drug Market Revenue and Forecast to 2028, by End User (USD Million)

Table 51. Rest of Europe: Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, By Cancer Type (US$ Mn)

Table 52. Rest of Europe: Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, By Route of Administration (US$ Mn)

Table 53. Rest of Europe: Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, by Drug Class (US$ Mn)

Table 54. Rest of Europe: Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, by Product (US$ Mn)

Table 55. Rest of Europe: Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, by End User (US$ Mn)

Table 56. Asia Pacific: Metastatic Cancer Drug Market, By Cancer Type – Revenue and Forecast to 2028 (USD Million)

Table 57. Asia Pacific: Metastatic Cancer Drug Market, By Route of Administration – Revenue and Forecast to 2028 (USD Million)

Table 58. Asia Pacific Metastatic Cancer Drug Market, by Drug Class– Revenue and Forecast to 2028 (USD Million)

Table 59. Asia Pacific Metastatic Cancer Drug Market, by Product – Revenue and Forecast to 2028 (USD Million)

Table 60. Asia Pacific Metastatic Cancer Drug Market, by End User– Revenue and Forecast to 2028 (USD Million)

Table 61. China: Metastatic Cancer Drug Market, By Cancer Type – Revenue and Forecast to 2028 (USD Million)

Table 62. China: Metastatic Cancer Drug Market, By Route of Administration – Revenue and Forecast to 2028 (USD Million)

Table 63. China: Metastatic Cancer Drug Market, by Drug Class– Revenue and Forecast to 2028 (USD Million)

Table 64. China: Metastatic Cancer Drug Market, by Product– Revenue and Forecast to 2028 (USD Million)

Table 65. China: Metastatic Cancer Drug Market, by End User– Revenue and Forecast to 2028 (USD Million)

Table 66. Japan: Metastatic Cancer Drug Market, By Cancer Type– Revenue and Forecast to 2028 (USD Million)

Table 67. Japan: Metastatic Cancer Drug Market, By Route of Administration– Revenue and Forecast to 2028 (USD Million)

Table 68. Japan: Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)

Table 69. Japan: Metastatic Cancer Drug Market, by Product– Revenue and Forecast to 2028 (USD Million)

Table 70. Japan: Metastatic Cancer Drug Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 71. India: Metastatic Cancer Drug Market, By Cancer Type– Revenue and Forecast to 2028 (USD Million)

Table 72. India: Metastatic Cancer Drug Market, By Route of Administration– Revenue and Forecast to 2028 (USD Million)

Table 73. India: Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)

Table 74. India: Metastatic Cancer Drug Market, by Product– Revenue and Forecast to 2028 (USD Million)

Table 75. India: Metastatic Cancer Drug Market, by End User– Revenue and Forecast to 2028 (USD Million)

Table 76. Australia: Metastatic Cancer Drug Market, By Cancer Type – Revenue and Forecast to 2028 (USD Million)

Table 77. Australia: Metastatic Cancer Drug Market, By Route of Administrations – Revenue and Forecast to 2028 (USD Million)

Table 78. Australia: Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)

Table 79. Australia: Metastatic Cancer Drug Market, by Product– Revenue and Forecast to 2028 (USD Million)

Table 80. Australia: Metastatic Cancer Drug Market, by End User– Revenue and Forecast to 2028 (USD Million)

Table 81. South Korea: Metastatic Cancer Drug Market, By Cancer Type – Revenue and Forecast to 2028 (USD Million)

Table 82. South Korea: Metastatic Cancer Drug Market, By Route of Administration – Revenue and Forecast to 2028 (USD Million)

Table 83. South Korea: Metastatic Cancer Drug Market, by Drug Class– Revenue and Forecast to 2028 (USD Million)

Table 84. South Korea: Metastatic Cancer Drug Market, by Product– Revenue and Forecast to 2028 (USD Million)

Table 85. South Korea: Metastatic Cancer Drug Market, by End User– Revenue and Forecast to 2028 (USD Million)

Table 86. Rest of Asia Pacific: Metastatic Cancer Drug Market, By Cancer Type – Revenue and Forecast to 2028 (USD Million)

Table 87. Rest of Asia Pacific: Metastatic Cancer Drug Market, By Route of Administration – Revenue and Forecast to 2028 (USD Million)

Table 88. Rest of Asia Pacific: Metastatic Cancer Drug Market, by Drug Class– Revenue and Forecast to 2028 (USD Million)

Table 89. Rest of Asia Pacific: Metastatic Cancer Drug Market, by Product– Revenue and Forecast to 2028 (USD Million)

Table 90. Rest of Asia Pacific: Metastatic Cancer Drug Market, by End User– Revenue and Forecast to 2028 (USD Million)

Table 91. Middle East & Africa Metastatic Cancer Drug Market, by Cancer Type– Revenue and Forecast to 2028 (USD Million)

Table 92. Middle East & Africa Metastatic Cancer Drug Market, by Route of Administration– Revenue and Forecast to 2028 (USD Million)

Table 93. Middle East & Africa Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)

Table 94. Middle East & Africa Metastatic Cancer Drug Market, by Product – Revenue and Forecast to 2028 (USD Million)

Table 95. Middle East & Africa Metastatic Cancer Drug Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 96. Saudi Arabia Metastatic Cancer Drug Market, by Cancer Type– Revenue and Forecast to 2028 (USD Million)

Table 97. Saudi Arabia Metastatic Cancer Drug Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

Table 98. Saudi Arabia Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)

Table 99. Saudi Arabia Metastatic Cancer Drug Market, by Product – Revenue and Forecast to 2028 (USD Million)

Table 100. Saudi Arabia Metastatic Cancer Drug Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 101. UAE Metastatic Cancer Drug Market, by Cancer Type– Revenue and Forecast to 2028 (USD Million)

Table 102. UAE Metastatic Cancer Drug Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

Table 103. UAE Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)

Table 104. UAE Metastatic Cancer Drug Market, by Product – Revenue and Forecast to 2028 (USD Million)

Table 105. UAE Metastatic Cancer Drug Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 106. South Africa Metastatic Cancer Drug Market, by Cancer Type– Revenue and Forecast to 2028 (USD Million)

Table 107. South Africa Metastatic Cancer Drug Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

Table 108. South Africa Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)

Table 109. South Africa Metastatic Cancer Drug Market, by Product – Revenue and Forecast to 2028 (USD Million)

Table 110. South Africa Metastatic Cancer Drug Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 111. Rest of Middle East & Africa Metastatic Cancer Drug Market, by Cancer Type– Revenue and Forecast to 2028 (USD Million)

Table 112. Rest of Middle East & Africa Metastatic Cancer Drug Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

Table 113. Rest of Middle East & Africa Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)

Table 114. Rest of Middle East & Africa Metastatic Cancer Drug Market, by Product – Revenue and Forecast to 2028 (USD Million)

Table 115. Rest of Middle East & Africa Metastatic Cancer Drug Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 116. South and Central America: Metastatic Cancer Drug Market, by Cancer Type – Revenue and Forecast to 2028 (USD Million)

Table 117. South and Central America: Metastatic Cancer Drug Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

Table 118. South and Central America: Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)

Table 119. South and Central America: Metastatic Cancer Drug Market, by Product– Revenue and Forecast to 2028 (USD Million)

Table 120. South and Central America: Metastatic Cancer Drug Market, by End User– Revenue and Forecast to 2028 (USD Million)

Table 121. Brazil: Metastatic Cancer Drug Market, by Cancer Type – Revenue and Forecast to 2028 (USD Million)

Table 122. Brazil: Metastatic Cancer Drug Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

Table 123. Brazil: Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)

Table 124. Brazil: Metastatic Cancer Drug Market, by Product– Revenue and Forecast to 2028 (USD Million)

Table 125. Brazil: Metastatic Cancer Drug Market, by End User– Revenue and Forecast to 2028 (USD Million)

Table 126. Argentina: Metastatic Cancer Drug Market, by Cancer Type – Revenue and Forecast to 2028 (USD Million)

Table 127. Argentina: Metastatic Cancer Drug Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

Table 128. Argentina: Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)

Table 129. Argentina: Metastatic Cancer Drug Market, by Product– Revenue and Forecast to 2028 (USD Million)

Table 130. Argentina: Metastatic Cancer Drug Market, by End User– Revenue and Forecast to 2028 (USD Million)

Table 131. Rest of South and Central America: Metastatic Cancer Drug Market, by Cancer Type – Revenue and Forecast to 2028 (USD Million)

Table 132. Rest of South and Central America: Metastatic Cancer Drug Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

Table 133. Rest of South and Central America: Metastatic Cancer Drug Market, by Drug Class – Revenue and Forecast to 2028 (USD Million)

Table 134. Rest of South and Central America: Metastatic Cancer Drug Market, by Product– Revenue and Forecast to 2028 (USD Million)

Table 135. Rest of South and Central America: Metastatic Cancer Drug Market, by End User– Revenue and Forecast to 2028 (USD Million)

Table 136. Recent Inorganic Growth Strategies in the Metastatic Cancer Drug Market

Table 137. Recent Organic Growth Strategies in the Metastatic Cancer Drug Market

Table 138. Glossary of Terms, Metastatic Cancer Drugs Market

LIST OF FIGURES.

Figure 1. Metastatic Cancer Drugs Market Segmentation

Figure 2. Metastatic Cancer Drugs Segmentation, By Region

Figure 3. Global Metastatic Cancer Drugs Market Overview

Figure 4. The PARP Inhibitors Segment Held The Largest Share of Drug Class Segment in Metastatic Cancer Drugs Market

Figure 5. Asia-Pacific Region Is Expected to Show Remarkable Growth During the Forecast Period

Figure 6. Global Metastatic Cancer Drugs Market, By Geography (US$ Million)

Figure 7. Global Metastatic Cancer Drugs Market- Leading Country Markets (US$ Million)

Figure 8. Global Metastatic Cancer Drugs Market, Industry Landscape

Figure 9. North America PEST Analysis

Figure 10. Europe PEST Analysis

Figure 11. Asia Pacific PEST Analysis

Figure 12. South & Central America PEST Analysis

Figure 13. Middle East & Africa PEST Analysis

Figure 14. Expert Opinion

Figure 15. Metastatic Cancer Drugs Market Impact Analysis of Driver and Restraints

Figure 16. Global Metastatic Cancer Drugs Market – Revenue Forecast and Analysis – 2021- 2028

Figure 17. Global Metastatic Cancer Drugs Market – By Geography Forecast and Analysis – 2021- 2028.

Figure 18. Global Metastatic Cancer Drugs Market – Market Potential Analysis, By Region

Figure 19. Global Metastatic Cancer Drugs Market – Comparative Company Analysis

Figure 20. Global Metastatic Cancer Drugs Market – Growth Strategy Analysis

Figure 21. Market Positioning of Key Players in Global Metastatic Cancer Drugs Market

Figure 22. Metastatic Cancer Drug Market Revenue Share, by Cancer Type (2021 and 2028)

Figure 23. Breast Cancer: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 24. Lung Cancer: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 25. Liver Cancer: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 26. Hematological Cancer: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 27. Brain Cancer: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 28. Prostate Cancer: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 29. Pancreatic Cancer: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 30. Others: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 31. Metastatic Cancer Drug Market, by Route of Administration, 2021 and 2028 (%)

Figure 32. Intravenous: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 33. Intramuscular: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 34. Oral: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 35. Others: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 36. Metastatic Cancer Drug Market, by Drug Class, 2021 and 2028 (%)

Figure 37. HER2 Inhibitors: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 38. Immune Checkpoints Inhibitors: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 39. PARP Inhibitors: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 40. Kinase Inhibitors: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 41. Others: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 42. Metastatic Cancer Drug Market, by Product, 2021 and 2028 (%)

Figure 43. Branded: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 44. Generics and Biosimilars: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 45. Metastatic Cancer Drug Market, by End User, 2021 and 2028 (%)

Figure 46. Hospitals: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 47. Specialty Clinics: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 48. Others: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

Figure 49. North America: Metastatic Cancer Drug Market, by Key Country – Revenue (2021) (USD Million)

Figure 50. North America: Metastatic Cancer Drug Market Revenue and Forecast to 2028 (USD Million)

Figure 51. North America: Metastatic Cancer Drug Market, by Country, 2021 & 2028 (%)

Figure 52. US: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

Figure 53. Canada: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

Figure 54. Mexico: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

Figure 55. Europe: Metastatic Cancer Drug Market Revenue Overview, by Country, 2021 (US$ MN)

Figure 56. Europe: Metastatic Cancer Drug Market - Revenue and Forecasts to 2028 (US$ Mn)

Figure 57. Europe: Metastatic Cancer Drug Market - Revenue and Forecasts to 2028, By Country (%)

Figure 58. UK: Metastatic Cancer Drug Market - Revenue and Forecasts to 2028 (US$ Mn)

Figure 59. Germany Metastatic Cancer Drug Market - Revenue and Forecasts to 2028 (US$ Mn)

Figure 60. France Metastatic Cancer Drug Market - Revenue and Forecasts to 2028 (US$ Mn)

Figure 61. Italy Metastatic Cancer Drug Market - Revenue and Forecasts to 2028 (US$ Mn)

Figure 62. Spain Metastatic Cancer Drug Market - Revenue and Forecasts to 2028 (US$ Mn)

Figure 63. Rest of Europe: Metastatic Cancer Drug Market - Revenue and Forecasts to 2028 (US$ Mn)

Figure 64. Asia Pacific: Metastatic Cancer Drug Market, by Key Country – Revenue (2021) (USD Million)

Figure 65. Asia Pacific Metastatic Cancer Drug Market Revenue and Forecast to 2028 (USD Million)

Figure 66. Asia Pacific: Metastatic Cancer Drug Market, by Country, 2021 & 2028 (%)

Figure 67. China: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

Figure 68. Japan: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

Figure 69. India: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

Figure 70. Australia: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

Figure 71. South Korea: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

Figure 72. Rest of Asia Pacific: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

Figure 73. Middle East and Africa: Metastatic Cancer Drugs Market, by Key Country – Revenue (2021) (US$ ‘Million)

Figure 74. Middle East and Africa: Metastatic Cancer Drugs Market Revenue and Forecast to 2028 (US$ ‘Million)

Figure 75. Middle East & Africa: Metastatic Cancer Drug Market, by Country, 2021 & 2028 (%)

Figure 76. Saudi Arabia: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

Figure 77. UAE: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

Figure 78. South Africa: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

Figure 79. Rest of Middle East and Africa: Metastatic Cancer Drug Market - Revenue and Forecast to 2028 (USD Million)

Figure 80. South and Central America: Metastatic Cancer Drugs Market, by Key Country – Revenue (2021) (US$ ‘Million)

Figure 81. South and Central America Metastatic Cancer Drug Market Revenue and Forecast to 2028 (USD Million)

Figure 82. South and Central America: Metastatic Cancer Drug Market, by Country, 2021 & 2028 (%)

Figure 83. Brazil: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

Figure 84. Argentina: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

Figure 85. Rest of South and Central America: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (USD Million)

Figure 86. Impact Of COVID-19 Pandemic in North American Country Markets

Figure 87. Impact Of COVID-19 Pandemic in Europe Country Markets

Figure 88. Impact Of COVID-19 Pandemic in Asia-Pacific Country Markets

Figure 89. Impact Of COVID-19 Pandemic in Middle East & Africa Country Markets

Figure 90. Impact of COVID-19 Pandemic in South and Central American Countries

Figure 91. Growth Strategies in the Metastatic Cancer Drug Market, 2021-2028

The List of Companies - Metastatic Cancer Drug Market

1. AbbVie Inc.

2. Amgen Inc.

3. Bristol-Myers Squibb Company

4. F. HOFFMANN-LA ROCHE LTD.

5. Novartis AG

6. ASTRAZENECA PLC.

7. Eli Lilly and Company

8. MERCK KGaA

9. Pfizer Inc. (Arena Pharmaceutical GmbH)

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the metastatic cancer drug market.

• Highlights key business priorities in order to assist companies to realign their business strategies.

• The key findings and recommendations highlight crucial progressive industry trends in the global metastatic cancer drug market, thereby allowing players across the value chain to develop effective long-term strategies.

• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

• Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.

TOP